#USA #San Diego #GLP-1 #Valisure #FuturHealth

FuturHealth Releases Promising New Efficacy Data

FuturHealth, a top provider of personalized weight-loss solutions, is making headlines with its recent release of efficacy data obtained from an extensive retrospective study. Conducted in collaboration with InCSD, the study evaluated the weight management of over 33,000 patients and revealed that the combination of FuturHealth's Program with GLP-1 treatments like Semaglutide and Tirzepatide greatly enhances weight loss outcomes compared to the medications alone.

In detail, the findings indicate further improvements: patients utilizing the FuturHealth Program saw a 58.5% greater reduction in body weight with Semaglutide and an 18.3% higher result with Tirzepatide compared to using these medications solely. Results noted that users on the FuturHealth Program lost, on average, 30 lbs within six months for Tirzepatide and 25 lbs for Semaglutide. Additionally, average reductions in BMI were 4.76 kg/m² for Tirzepatide users and 4.1 kg/m² for those taking Semaglutide.

Luke Mahoney, CEO of FuturHealth, stated, "At FuturHealth, we contend that effective weight management involves more than just medication. We create a sustainable approach to health by combining the right treatment with a support system. These results bolster our confidence in our method, highlighting the significant benefits of a holistic approach."

The company also announced a strategic partnership with Valisure, an independent laboratory specializing in chemical analysis for quality assurance, to ensure safety and quality standards for compounded GLP-1 medications. This collaboration stands to improve trust in the medication supply chain, ensuring thorough testing and verification against contaminants, including carcinogens.

David Light, Co-Founder and President of Valisure, expressed enthusiasm about the partnership, aiming to add a sense of independent verification in the fast-evolving healthcare sector, enhancing patient safety and experiences.

Dr. Michael Snyder, Medical Director at the Bariatric Surgery Center at Rose Medical Center, remarked that this research represents a significant examination of real-world integrated weight management, validating the advantages of combining GLP-1 treatments with structured nutrition and lifestyle interventions.

Individual cases may vary based on adherence to the program alongside baseline weight and lifestyle, and the full findings from the retrospective study can be accessed at FuturHealth's website. The company continues to revolutionize the weight management landscape, providing personalized support alongside scientifically-backed solutions.

For more information about FuturHealth and its innovative strategies in weight management, check out their website at www.fh.co.

About FuturHealth

FuturHealth is committed to personalizing weight-loss strategies, working in tandem with doctors and nutrition experts to develop effective solutions tailored to individual needs. With a strong network that spans across the U.S., they aim to not just provide weight-loss assistance but to empower individuals towards their long-term health success, having positively impacted over 1.5 million patients.

About Valisure

Valisure plays a vital role in enhancing medication quality assurance through meticulous evaluations of supplied products, addressing significant gaps in the healthcare supply chain. Their work ensures that patients receive reliable medications, enhancing overall trust in this crucial sector.